吉利德科学(GILD.US)盘前涨超2.1%，报110.3美元。消息面上，吉利德科学宣布，备受业界关注的HIV-1衣壳抑制剂来那卡帕韦(Lenacapavir，商品名Yeztugo)已经获得美国食品药品监督管理局批准用于暴露前预防(PrEP)用药。在一项后期试验中，使用来那卡帕韦的两千多人中仅出现两例感染，使得HIV感染风险有效降低96%。在另一项针对生理女性、且自我认知为女性的试验中，所有参与者均未感染病毒，有效性达到100%。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.